Meta-Analysis

Gonadotropin-Releasing Hormone Analogue Stimulation Test Versus Venous Sampling in Postmenopausal Hyperandrogenism

Eng-Loon Tng¹ and Jeanne May May Tan²

¹Department of Medicine, Ng Teng Fong General Hospital, Singapore 609606; and ²National Neuroscience Institute, Tan Tock Seng Hospital, Singapore 308433

ORCID number: 0000-0002-4104-6238 (E.-L. Tng).

Abbreviations: APG, adrenal:peripheral gradient; CT, computed tomography; DHEAS, dehydroepiandrosterone sulfate; FN, false negative; FP, false positive; GAST, GnRH analogue stimulation test; GnRH, gonadotropin-releasing hormone; GnRHa, GnRH analogue; HSROC, hierarchical summary receiver operator characteristics curve; OH, ovarian hyperthecosis; OPG, ovarian:peripheral gradient; PET/CT, positron emission tomography/computed tomography; PH, postmenopausal hyperandrogenism; ROC, receiver operator characteristic; SOAVC, selective ovarian and adrenal vein catheterization; TN, true negative; TP, true positive; VT, virilizing tumor.

Received: 17 September 2020; Editorial Decision: 26 October 2020; First Published Online: 5 November 2020; Corrected and Typeset: 5 December 2020.

Abstract

Postmenopausal hyperandrogenism can be due to excessive androgen secretion from adrenal or ovarian virilizing tumors or nonneoplastic conditions. The etiology of postmenopausal hyperandrogenism can be difficult to discern because of limited accuracy of current diagnostic tests. This systematic review compares the diagnostic accuracy of the gonadotropin-releasing hormone (GnRH) analogue stimulation test against selective ovarian and adrenal vein sampling of androgens in distinguishing neoplastic from nonneoplastic causes of postmenopausal hyperandrogenism. Diagnostic test accuracy studies on these index tests in postmenopausal women were selected based on preestablished criteria. The true positive, false positive, false negative, and true negative values were extracted and meta-analysis was conducted using the hierarchical summary receiver operator characteristics curve method. The summary sensitivity of the GnRH analogue stimulation test is 10% (95% confidence interval [CI], 1.1%-46.7%) and that for selective venous sampling is 100% (95% CI, 0%-100%). Both tests have 100% specificity. There is limited evidence for the use of either test in identifying virilizing tumors in postmenopausal hyperandrogenism.

Key Words: Postmenopausal hyperandrogenism, gonadotropin-releasing hormone analogue stimulation test, selective adrenal and ovarian vein catheterization, virilizing tumors, ovarian neoplasms, adrenal neoplasms
Postmenopausal hyperandrogenism (PH) is a state of androgen excess originating from the adrenal glands or the ovaries, manifesting with increased terminal hair growth or virilization [1]. Current diagnostic tests may not be able to distinguish PH due to virilizing tumors (VT) from other forms of functional hyperandrogenism. Basal testosterone levels above 100 to 140 ng/dL in conjunction with abrupt onset and rapid progression of hyperandrogenic features may indicate the presence of VT [1]. However, basal androgen levels overlap between various etiologies of PH [2-4] and diagnostic cutoff values vary widely [5-8]. Furthermore, VT may not secrete substantial amounts of androgens [2, 9, 10]. Small VT may evade detection on scans [11-13]. Scans are also not helpful in distinguishing adrenal VT from incidentalomas [14-16] and ovarian VT can coexist with ovarian hyperthecosis (OH) [13]. Positron emission tomography/computed tomography (PET/CT) is not well-studied in PH [1, 11]. The gonadotropin-releasing hormone (GnRH) analogue stimulation test (GAST) has been used to evaluate women with hyperandrogenism. Following a single intramuscular injection of long-acting or short-acting GnRH analogue (GnRHa), ovarian production of androgen should be suppressed [17]. With short-acting GnRHa, testosterone should fall by at least 50% from baseline value while with long-acting GnRHa, testosterone levels fall into the reference interval [3]. GAST is noninvasive, does not require technical expertise, and can be conducted in the outpatient setting. However, it is performed over 3 months so the diagnosis of VT can be delayed. Selective ovarian and adrenal vein catheterization (SOAVC) localizes VT based on differential gradients in androgen levels between ovarian, adrenal, and peripheral veins. SOAVC requires expertise and success rates in cannulating all veins are from 26% to 66% [18-20]. It is invasive, exposes patients to radiation, and carries the risk for contrast nephropathy. Furthermore, SOAVC is unreliable when ovarian VT and OH coexist.

Rational for Conducting This Systematic Review

The investigations for PH have limited diagnostic accuracy and can be invasive. As GAST is a simple and noninvasive test, we compared its diagnostic accuracy against SOAVC in distinguishing neoplastic from nonneoplastic causes of PH. This is the first systematic review on this topic.

Objectives

The aim of this systematic review is to compare the diagnostic accuracy of GAST and SOAVC in distinguishing neoplastic from nonneoplastic causes of PH. The reference standard is the combination of clinical evaluation, biochemical evaluation, abdominal and pelvic imaging, and histological confirmation of tumor. The aim was achieved by:

1. Performing a systematic review of all diagnostic test accuracy studies evaluating the use of GAST and SOAVC in PH
2. Performing meta-analysis if the results are sufficiently homogeneous and providing a narrative summary of the results if otherwise

Methods

Eligibility Criteria

Diagnostic test accuracy studies in which information on index tests and reference standards are available were included for analysis. Only studies that included postmenopausal women were included. There was no restriction on the language, publication status, or date of publication of studies.

Participants

Studies which reported the accuracy of GAST, SOAVC, and reference standards in identifying sources of androgen secretion in PH were included.

Index Tests

GAST using short-acting or long-acting GnRHa and SOAVC.

Reference Standard

The identification of sources of androgen secretion in PH based on clinical features, basal androgen levels, imaging tests such as computed tomography (CT), magnetic resonance imaging, and/or ultrasound of the adrenal glands and ovaries, laparoscopic findings (where available), follow-up data, and histology is regarded as the reference standard.

Target Condition Being Diagnosed

Postmenopausal hyperandrogenism.

Exclusion Criteria

Studies unrelated to PH, GAST, or SOAVC were excluded. Studies that did not include postmenopausal women were excluded.
Outcomes
True positive (TP), false positive (FP), false negative (FN), and true negative (TN) values of each test were extracted.

Assessment of Methodological Quality
Quality of evidence of studies was assessed by 2 reviewers (E.L.T. and J.M.M.T.) using the QUADAS-2 tool. The reasons for classifying risk of bias as low, unclear, or high for each domain were recorded.

Statistical Analysis and Data Synthesis
Characteristics of included and excluded studies were summarized. Meta-analysis was conducted on studies that reported TP, FP, FN, and TN values. The hierarchical summary receiver operator characteristics curve (HSROC) method was used in meta-analysis as this model allows combination of different cutoff values of GAST and SOAVC in the studies. It also allows comparison of ROCs of different androgen assays in the studies. Statistical analysis was performed using the online app MetaDTA: Diagnostic Test Accuracy Meta-Analysis v1.25 [21]. Flow diagrams, risk of bias charts, forest plots, and ROCs were generated using the Review Manager 5.3 software [22]. Summary of findings tables were generated using the GRADEpro GDT online app [23].

Assessment of Reporting Bias
Reporting bias was assessed by comparing the number of studies that were performed against the number of studies that did not report the accuracy measure.

The following are found in the supplementary material [24]:

1. Methods (information sources, data management, selection process, data collection process, and data items)
2. Details of included studies
3. Details of excluded studies
4. Risk of bias and applicability concerns assessment
5. Summary of findings tables
6. Assessment of reporting bias

Search Strategy
The search strategies for this systematic review can be found on PROSPERO (https://www.crd.york.ac.uk/PROSPERO/).

Results
Results of the Search
A total of 13,597 records were retrieved from MEDLINE (2,374), Embase (8,387), CINAHL (415), DARE (34), Cochrane Library (339), SCI Expanded (1,595), PROSPERO (19), ClinicalTrials.gov (60), and WHO ICTRP (374). A further 34 articles were found through manual searching of reference lists of shortlisted articles. The study flow diagram is shown in Fig. 1. Duplicates (3,088) were excluded, and 10,473 irrelevant studies were excluded after screening the titles and abstracts. Seventy articles were retrieved for full-text screening. Of these, 64 were excluded (see “F. Characteristics of excluded studies”). Ultimately 6 studies fulfilled the inclusion criteria: 3 studies on GAST and 3 studies on SOAVC. These 6 studies had sufficiently homogeneous data for meta-analysis.

Characteristics of Included Studies
The characteristics of included studies are summarized in Table 1.
**Table 1. Characteristics of Included Studies**

| Study            | Study characteristics and setting                                                                 | Index test                                                                                                     | Target condition and reference standard(s)                                                                 |
|------------------|-------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| **Bricaire 1991** | 16 patients with plasma testosterone levels exceeding 1.4 ng/mL and whom US and CT failed to locate VT. 6 were found to have VT (2 lipid cell tumors, 2 Leydig cell tumors, 1 serous papillary cystadenoma with functioning stroma, 1 adenocortical carcinoma), 6 had polycystic ovaries, 4 had stromal/hilar cell hyperplasia. Teaching hospital in France. | Bilateral ovarian-adrenal vein catheterization. Testosterone, androstenedione, cortisol, urine free cortisol, and 17-hydroxyprogesterone were measured using RIA. | Hyperandrogenism due to VT. Clinical evaluation, biochemical evaluation, abdominal and pelvic imaging, and histological confirmation of VT. |
| **Gomes 2016**    | 18 hyperandrogenic women with normal adrenal CT. 5 had VT (3 Leydig cell tumours, 1 steroid cell tumor, 1 teratoma), 13 had OH. University hospital in Brazil. | Leuprolide acetate 3.75mg was given every 30 days for 3 months. Positive test is defined as failure of testosterone to fall by more than 50% from baseline value. | Hyperandrogenemia of ovarian origin. Histological confirmation of VT. |
| **Kaltsas 2003**  | 42 women who underwent SOAVC. 8 had VT (2 adrenal adenomas, 1 Leydig cell tumor, 2 Sertoli-Leydig cell tumors, 1 hilus cell tumor, 1 granulosa cell tumor; histology not available for 1 patient). 30 had nontumoral hyperandrogenism. Results were not available in 4 patients. Tertiary hospital in the United Kingdom. | Transfemoral selective catheterization of ovarian and adrenal veins. Estradiol OPG >2 confirms cannulation of ovarian vein. | Hyperandrogenism due to VT. Clinical evaluation, biochemical evaluation, adrenal CT, pelvic ultrasound, and histological confirmation of VT. |
| **Pascale 1994**  | 5 women referred for clinical symptoms of virilization with testosterone levels greater than 7 nmol/L and normal DHEAS. 3 had VT (1 granulosa cell tumor, 1 hilus cell tumor, 1 Sertoli-Leydig cell tumor). 2 had OH. France. | Single intramuscular injection of 3.75mg of D-Trp-6-GnRH was given. Positive test was defined as failure of testosterone to fall into the range seen in controls. Testosterone, androstenedione, DHEA, DHEAS, FSH, and LH were measured by RIA before and 3 weeks after GnRHa administration. | Hyperandrogenism due to ovarian VT. |
Possible Sources of Heterogeneity

GAST

The conduct and cutoffs of the index tests were not standardized. Gomes et al [25] and Yance et al [13] administered 3 doses of leuprolide acetate over 3 months while Pascale et al [17] administered only a single dose of leuprolide acetate. Gomes et al and Yance et al defined a positive test as failure of testosterone to fall by more than 50% from baseline while Pascale et al defined a positive test as failure of testosterone to fall into the range seen in controls.

The reference standards were not standardized between studies. All studies established the reference standards based on clinical features, baseline androgen and gonadotropin levels, imaging tests, and histology. However, different types of scans were used. Gomes et al selected patients with normal adrenal glands based on CT scans. Pascale et al used pelvic ultrasound and adrenal CT while Yance et al used pelvic magnetic resonance imaging in 16 women, pelvic ultrasound in 32 women, and PET/CT in 5 women.

The androgen levels were reported using different units. Gomes et al and Yance et al reported testosterone levels in ng/dL. Yance et al measured testosterone using immunofluorometric assay (AutoDELFIA, WallacOy, Turku, Finland). Gomes et al did not report the type of assay for androgen measurement. Pascale et al reported testosterone in nmol/L and they used radioimmunoassay for their study.

SOAVC

The conduct and cutoffs of the index tests were not standardized. Kaltsas and colleagues [18] performed bilateral ovarian-adrenal vein catheterization in no particular order. Ovarian cannulation was confirmed using an ovarian:peripheral gradient (OPG) for estradiol above 2. Adrenal vein cannulation was confirmed using an adrenal:peripheral gradient (APG) for Sörensen 1986 [27] 75 women who underwent SOAVC between 1976 and 1986. 67 women had hyperandrogenism and 8 women were healthy volunteers with ovulatory cycles. 7 had VT (3 lipid cell tumors, 2 Leydig cell tumors, 2 Sertoli-Leydig cell tumors). 60 had nontumoral hyperandrogenism.

Department of Radiology, Klinikum Steglitz, Free University of Berlin, Germany.

Yance 2017 [13] 34 postmenopausal women with ovarian VT and OH were studied retrospectively. 13 had VT (5 Leydig cell tumors, 4 steroid cell tumors, 1 thecoma, 3 Sertoli-Leydig cell tumors). 21 had OH. Tertiary center in Brazil.

3.75mg of leuprolide acetate was given intramuscularly every 30 days for 3 months. Testosterone, estradiol, FSH, and LH were measured before and 30 days after the last GnRHa injection. Positive test was defined as failure of testosterone to fall by more than 50% from baseline value. Testosterone, estradiol, LH, and FSH were measured by immunofluorometric assay.

Hyperandrogenism due to VT. Clinical evaluation, biochemical evaluation, abdominal and pelvic imaging, endoscopy, and histological confirmation of VT.

Abbreviations: APG, adrenal:peripheral gradient; CT, computed tomography; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; GnRHa, GnRH analogue; LH, luteinizing hormone; OH, ovarian hyperthecosis; OPG, ovarian:peripheral gradient; RIA, radioimmunoassay; VT, virilizing tumor.
cortisol above 2. Bricaire and colleagues [26] preferentially cannulated the left ovarian vein first, followed by the left adrenal vein, then right ovarian vein, and lastly the right adrenal vein, although the sequence of sampling was not rigid. Patients were given meperidine and hydroxyzine prior to insertion of the catheter. No attempts at occluding other vessels were made during blood sampling. Cannulation was confirmed using fluoroscopic guidance. OPG and APG were not prespecified. Sörensen and colleagues [27] conducted transfemoral venous catheterization by the same radiologist and the veins were sampled in random sequence. Successful cannulation was established via fluoroscopy. No premedications were given. OPG and APG were not prespecified.

The study population differed between studies. Kaltsas and colleagues studied hyperandrogenized women who failed to suppress at least one androgen by 50% following a low-dose dexamethasone suppression test. Bricaire and colleagues studied women with baseline testosterone levels above 1.4 ng/mL. Sörensen and colleagues studied 67 women with clinical or biochemical features of hyperandrogenism or hyperandrogenemia and 8 healthy premenopausal women.

The reference standards were not standardized between studies. Kaltsas and colleagues had histological confirmation in 15 of the 16 subjects in their studies. Bricaire and colleagues had histological confirmation in patients with localizing gradient on venous catheterization but not in 10 patients without lateralizing gradients. Sörensen and colleagues had histological confirmation in 18 patients but not in 60 patients whom they assumed to have no VT based on negative imaging tests.

Different imaging techniques were used in the studies. Kaltsas and colleagues obtained transabdominal ultrasound of the ovaries in most of their subjects and transvaginal ultrasound in a minority of them. CT of the adrenal glands was obtained in all subjects in their study. Bricaire and colleagues obtained ultrasound of the pelvis and CT of the adrenal glands in their patients. Sörensen and colleagues performed retrograde venography, iodocholesterol isotopic scan, and angiography in some of their patients. They also performed laparoscopy to rule out macroscopic ovarian lesions.

The androgen levels were reported using different units. Kaltsas reported the units for testosterone, androstenedione, and dehydroepiandrosterone sulfate (DHEAS) in nmol/L. Bricaire reported testosterone in ng/mL. Sörensen and colleagues reported testosterone and DHEAS in ng/mL.

Different cutoff levels for localization were used by the authors. Kaltsas and colleagues defined localization as an OPG or APG for testosterone above 2. Sörensen and colleagues used an OPG for testosterone greater than 2.7 ng/mL to localize ovarian VT. No threshold values for OPG or APG were declared by Bricaire.

**Subgroup Analyses**

Subgroup analysis on postmenopausal women could not be done because Gomes et al did not report the number of postmenopausal women with and without VT. Kaltsas and colleagues had 4 postmenopausal women out of 42 subjects. All postmenopausal women had VT in this study so there is no control group for comparison. Only 4 studies remain after exclusion of these 2 studies and the number of postmenopausal women in these studies is small: Pascale et al had 4 postmenopausal women out of 5 subjects (2 had VT and 2 had OH), and Yance et al had 34 postmenopausal subjects in their study. Bricaire and colleagues had 6 postmenopausal women out of 16 subjects (2 had VT and 4 had OH), and Sörensen and colleagues had 5 postmenopausal women out of 75 subjects (4 had VT and 1 had OH).

**Sensitivity Analyses**

Kaltsas and colleagues had low success rate in 4-vessel cannulation for SOAVC, so lateralizing OPG and APG could not be established in 5 patients in the VT group and 2 patients in the non-VT group. Sensitivity analysis was conducted for the best-case scenario (no FN, minimal FP, and maximal TN) and worst-case scenario (maximal FN, maximal FP, and minimal TN).

**Characteristics of Excluded Studies**

Sixty-four studies were excluded (see supplemental material). Twenty studies were excluded because they were not diagnostic test accuracy studies [6, 10, 28-45]. Twenty-two studies were excluded because they did not evaluate the diagnostic accuracy of GAST or SOAVC [5, 7, 8, 46-64]. Twenty-eight studies were excluded because they did not include postmenopausal women [39, 42, 43, 49, 58, 59, 64-85]. One study was excluded because the authors did not provide the study details despite repeated requests [86].

**Findings: GAST vs SOAVC to Diagnose VT in PH**

Quality of evidence was described using the GRADE framework. Prevalence of VT was derived from 2 large observational studies [87, 88].

The TP, FP, FN, and TN values reported by Gomes et al are 1, 0, 4, and 13, respectively. GAST had a sensitivity of
20% (95% confidence interval [CI] 1%-72%) and specificity of 100% (95% CI, 75%-100%) in detecting VT.

The TP, FP, FN, and TN values reported by Pascale et al are 0, 0, 3, and 2, respectively. GAST had a sensitivity of 0% (95% CI, 0%-71%) and specificity of 100% (95% CI, 16%-100%) in detecting VT.

The TP, FP, FN, and TN values reported by Yance et al are 0, 0, 2, and 13, respectively. GAST had a sensitivity of 0% (95% CI, 0%-84%) and specificity of 100% (95% CI, 75%-100%) in detecting VT.

The TP, FP, FN, and TN values reported by Pascale et al are 0, 0, 3, and 2, respectively. GAST had a sensitivity of 0% (95% CI, 0%-71%) and specificity of 100% (95% CI, 16%-100%) in detecting VT.

The summary sensitivity for GAST is 10% (95% CI, 1.4%-46.7%) and the summary specificity is 100% (95% CI, 0%-100%). Out of 100 women with PH, GAST will fail to detect VT in 90 (95% CI, 53-99) women. Out of 100 women without PH, GAST will falsely detect VT in 0 (95% CI, 0-100) women. The summary negative likelihood ratio is 0.9 (95% CI, 0.714-1.086).

The TP, FP, FN, and TN values reported by Bricaire et al are 6, 0, 0, and 10 respectively. SOAVC had a sensitivity of 100% (95% CI, 54%-100%) and specificity of 100% (95% CI, 69%-100%) in detecting VT.

Kaltsas et al had 5 indeterminate cases in their study because 4-vessel cannulation failed. Based on a best-case scenario where all the unilateral OPG and APG correctly lateralizes the VT, the TP, FP, FN, and TN values will be 8, 5, 0, and 3 respectively, and the sensitivity will be 100% (95% CI, 63%-100%) and specificity will be 38% (95% CI, 9%-76%). Based on a worst-case scenario where all the unilateral OPG and APG lateralized VT incorrectly, the TP, FP, FN, and TN values will be 3, 7, 5, and 1 respectively, and the sensitivity will be 38% (95% CI, 9%-76%) and specificity will be 13% (95% CI, 0%-53%).

The TP, FP, FN, and TN values reported by Sörensen et al are 6, 0, 0, and 68 respectively. SOAVC had a sensitivity of 100% (95% CI, 54%-100%) and specificity of 100% (95% CI, 95%-100%) in detecting VT.

The summary sensitivity for SOAVC in the best-case scenario is 100% (95% CI, 17%-100%) and the summary specificity is 100% (95% CI, 9%-100%). Out of 100 women with PH, SOAVC will fail to detect VT in 0 (95% CI, 0–83) women. Out of 100 women without PH, SOAVC will falsely detect VT in 0 (95% CI, 0-91) women. The summary positive likelihood ratio is 74 480.42 (95% CI, −933 229 to 1 082 190) and the summary negative likelihood ratio is 0 (95% CI, −0.003 to 0.004). At a pretest probability of 0.2% [87, 88], the posttest probability of a positive test is 0.993 (95% CI, 1.000-1.001).

The forest plots for GAST and SOAVC are shown in Fig. 2 (best-case scenario) and Fig. 3 (worst-case scenario). The HSROCs for GAST versus SOAVC are shown in Fig. 4 (best-case scenario) and Fig. 5 (worst-case scenario). Table 2 shows the summary estimates for GAST and SOAVC.

The summary sensitivity of GAST is 10% and that for SOAVC is 100%. Both tests have 100% specificity. However, due to the small numbers of patients and studies, the 95% CI for all estimates are wide.

The summary sensitivity of SOAVC in the worst-case scenario is 100% (95% CI, 17%-100%) and the summary specificity is 100% (95% CI, 9%-100%). Out of 100 women with PH, SOAVC will fail to detect VT in 0 (95% CI, 0-97) women. Out of 100 women without PH, SOAVC will falsely detect VT in 0 (95% CI, 0-97) women. The summary positive likelihood ratio is 12 216.53 (95% CI, −175 765 to 200 197.7) and the summary negative likelihood ratio is 0 (95% CI, 0-0). At a pretest probability of 0.2%, the posttest probability of a positive test is 0.961 (95% CI, 0.998-1.003).

The summary positive likelihood ratio is 12 216.53 (95% CI, −175 765 to 200 197.7) and the summary negative likelihood ratio is 0 (95% CI, 0-0). At a pretest probability of 0.2%, the posttest probability of a positive test is 0.961 (95% CI, 0.998-1.003).

The forest plots for GAST and SOAVC are shown in Fig. 2 (best-case scenario) and Fig. 3 (worst-case scenario). The HSROCs for GAST versus SOAVC are shown in Fig. 4 (best-case scenario) and Fig. 5 (worst-case scenario). Table 2 shows the summary estimates for GAST and SOAVC.

### Discussion

#### Summary of Main Results

The summary sensitivity of GAST is 10% and that for SOAVC is 100%. Both tests have 100% specificity. However, due to the small numbers of patients and studies, the 95% CI for all estimates are wide.

#### Strengths of This Study

This is the first systematic review on the diagnostic accuracy of GAST and SOAVC in identifying the source of androgen secretion in PH. There is no Cochrane review on this topic.

---

**Figure 2.** Forest plot: GAST versus SOAVC (best-case scenario) [13, 17, 18, 25-27].
An extensive search of multiple databases was performed and the risk of errors in study selection and data extraction is reduced as 2 reviewers independently reviewed the articles. The use of HSROC method allows combination of different thresholds used for diagnosing PH by the different assays and it also allows comparison of ROCs of the various androgen assays.

**Weaknesses of This Study**
Most of the included studies are of poor methodological quality and are at high risk for bias based on the QUADAS-2 tool. Heterogeneity arising from the lack of standardization of the index tests and reference standards may undermine the comparison between the index tests. The findings of this study may not be valid in centers that conduct the index tests differently.
The small number of included studies led to low power in the summary estimates so differences between the index tests may not be detected. The summary estimates are imprecise so the findings of this meta-analysis must be interpreted with caution. Subgroup analysis could not be performed on postmenopausal subjects so the results of this meta-analysis may not be extrapolated to postmenopausal women.

**Applicability of Findings**

The studies were all conducted in tertiary referral centers so the findings may not apply to general settings. A single radiologist performed SOAVC over many years for most of the studies so the findings may not apply to inexperienced radiologists. The latest studies were done in 2003 and improvements in biochemical and radiological investigations since

---

**Table 2. Summary Estimates**

| Study                        | Summary sensitivity | Summary specificity | Summary positive likelihood ratio | Summary negative likelihood ratio |
|------------------------------|---------------------|---------------------|-----------------------------------|----------------------------------|
| GAST with testosterone       | 10% (95% CI, 1.1%-46.7%) | 100% (95% CI, 0%-100%) | - infinity                        | 0.9 (95% CI, 0.714-1.086)       |
| SOAVC (Best-case scenario)   | 100% (95% CI, 0%-100%) | 100% (95% CI, 0.3%-100%) | 12 216.53 (95% CI, −175 765 to 200 197.7) | 0 (95% CI, 0-0)                 |
| SOAVC (Worst-case scenario)  | 100% (95% CI, 1.7%-100%) | 100% (95% CI, 9%-100%) | 74 480.42 (95% CI, −933 229 to 1 082 190) | 0 (95% CI, −0.003 to 0.004)     |

Abbreviations: GAST, GnRH analogue stimulation test; SOAVC, selective ovarian and adrenal vein catheterization.
2003 may invalidate the comparisons in this meta-analysis. As this is the only meta-analysis on this topic, further studies are needed to determine the reproducibility of our results.

Conclusions

Implications for Practice
There is limited evidence on the use of GAST and SOAVC in localizing VT in PH.

Implications for Research
Properly conducted diagnostic test accuracy studies on GAST and SOAVC in postmenopausal women are needed. Investigators should report the TP, FN, and TN values such that sensitivity and specificity of the tests can be compared. Researchers should standardize the diagnostic criteria for PH so that index tests can be compared against standardized reference standards.

Acknowledgments

Financial Support: There was no financial support or sponsor for this review.

Author Contributions: Eng-Loon Tng designed and drafted the manuscript. Eng-Loon Tng and Jeanne May May Tan conducted literature searches; performed screening of titles, abstracts, and full-text articles; extracted data; conducted analysis; and wrote the review.

Registration number: CRD42020162573

Additional Information

Correspondence: Eng-Loon Tng, MBBS, MMED, MSc, Department of Medicine, Ng Teng Fong General Hospital, Tower A, Level 8, 1 Jurong East Street 21, Singapore 609606. E-mail: Eng_Loon_Tng@nuhs.edu.sg.

Disclosure Summary: Eng-Loon Tng and Jeanne May May Tan have no conflicts of interest to declare.

Data Availability: Some or all data generated or analyzed during this study are included in this published article or in the data repository listed [24].

References and Notes

1. Markopoulos MC, Kassi E, Alexandraki KT, Mastorakos G, Kaltsas G. Hyperandrogenism after menopause. Eur J Endocrinol. 2015;172(2):R79-R91.
2. Azziz R, Carmina E, Dewailly D, et al.; Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-488.
3. Bahaeidein E, Brassill MJ. Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women. Endocrinol Diabetes Metab Case Rep. 2018; 2018:18-0084. doi:10.1530/EDM-18-0084.
4. Kamenicky P, Houdoin L, Ferlicot S, et al. Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clin Endocrinol (Oxf). 2007;66(6):778-788.
5. Derksen J, Nagesser SK, Meinders AE, Haak HR, van de Velde CJ. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med. 1994;331(15):968-973.
6. Friedman CI, Schmidt GE, Kim MH, Powell J. Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol. 1983;143(1):44-49.
7. Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003;88(6):2634-2643.
8. Sarfati J, Bachelot A, Coussieu C, Meduri G, Touraine P; Study Group Hyperandrogenism in Postmenopausal Women. Impact of clinical, hormonal, radiological, and immunohistochemical studies on the diagnosis of postmenopausal hyperandrogenism. Eur J Endocrinol. 2011;165(5):779-788.
9. Lobo RA. Ovarian hyperandrogenism and androgen-producing tumors. Endocrinol Metab Clin North Am. 1991;20(4):773-805.
10. Surrey ES, de Ziegler D, Gambone JC, Judd HL. Preoperative localization of androgen-secreting tumors: clinical, endocrinologic, and radiologic evaluation of ten patients. Am J Obstet Gynecol. 1988;158(6 Pt 1):1313-1322.
11. Brown DL, Henrichsen TL, Clayton AC, Hudson SB, Coddington CC 3rd, Vella A. Ovarian stromal hyperthecosis: sonographic features and histologic associations. J Ultrasound Med. 2009;28(5):587-593.
12. Horta M, Cunha TM. Sex cord-stromal tumors of the ovary: a comprehensive review and update for radiologists. Diagn Interv Radiol. 2015;21(4):277-286.
13. Yance VRV, Marcondes JAM, Rocha MP, et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur J Endocrinol. 2017;177(1):93-102.
14. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16(4):460-484.
15. Young WF Jr. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am. 2000;29(1):159-185, x.
16. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601-610.
17. Pascale MM, Pugart A, Roberts M, et al. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol (Oxf). 1999;41(5):571-576.
18. Kaltsas GA, Mukherjee JJ, Kola B, et al. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women? Clin Endocrinol (Oxf). 2003;59(1):34-43.
19. Levens ED, Whitcomb BW, Csokmay JM, Nieman LK. Selective venous sampling for androgen-producing ovarian pathology. Clin Endocrinol (Oxf). 2009;70(4):606-614.
20. Merz E, Miric-Tesanic D, Bahlmann F, Weber G, Wellek S. Sonographic size of uterus and ovaries in pre- and postmenopausal women. Ultrasound Obstet Gynecol. 1996;7(1):38-42.
21. Freeman SC, Kerby CR, Patel A, Cooper NJ, Quinn T, Sutton AJ. Development of an interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test accuracy studies: MetaDTA. *BMC Med Res Methodol.* 2019;19(1):81.

22. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014 [computer program].

23. GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.). gradepro.org. [Computer program].

24. GnRH test versus selective ovarian and adrenal vein sampling in postmenopausal hyperandrogenism. Zenodo; 2020. doi:10.5281/zenodo.3967869.

25. Gomes LG, Vanc VdRV, Rocha MP, et al. AGnRH Suppression Test Is Not a Useful Tool in the Differential Diagnosis of Hyperandrogenism of Ovarian Origin. SUN 141. *Endocr Rev.* 2016;37(Suppl 1).

26. Bricaire C, Raynaud A, Benotmane A, et al. Selective venous catheterization in the evaluation of hyperandrogenism. *J Endocrinol Invest.* 1991;14(11):949-956.

27. Sörensen R, Moltz L, Schwartz U. Technical difficulties of selective venous blood sampling in the differential diagnosis of female hyperandrogenism. *Cardiovasc Intervent Radiol.* 1986;9(2):75-82.

28. Adashi EY. Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism. *Fertil Steril.* 1990;53(5):765-779.

29. Balbi GC, Passaro M, Cirelli G, et al. [Use of GnRH analogues in the treatment of virilizing tumors]. *Minerva Ginecol.* 2001;53(1 Suppl 1):139-145.

30. Bardin CW, Mahoudeau JA. Dynamics of androgen metabolism in women with hirsutism. *Ann Clin Res.* 1970;2(4):251-262.

31. Barth JH, Jenkins M, Belchetz PE. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women. *Clin Endocrinol (Oxf).* 1997;46(2):123-128.

32. Bidzińska B, Tworowska U, Demissie M, Milewicz A. Modified dexamethasone and gonadotropin-releasing hormone agonist (Dx-GnRHa) test in the evaluation of androgen source(s) in hirsute women. *Preegl Lek.* 2000;57(7-8):393-396.

33. Chao HT, Wang PH, Lin HD. Gonadotropin-releasing hormone agonist as a neoadjuvant therapy for Sertoli-Leydig cell tumors of the ovary. *Int J Gynaecol Obstet.* 1999;66(2):189-190.

34. Cheah SK, Miremadi A, Khan S, Mathews A, Krishnan S. Localisation challenges in postmenopausal hyperandrogenism. Paper presented at: Society for Endocrinology BES 2018; Endocrine Abstracts. 2018;59:EP95. doi:10.1540/endoabs.59.EP95

35. Chen H, Liu Y, Shen LF, Jiang MJ, Yang ZE, Fang GP. Ovarian thecoma-fibroma groups: clinical and sonographic features with pathological comparison. *J Ovarian Res.* 2016;9(1):81.

36. Cohen I, Nabriski D, Fishman A. Noninvasive test for the diagnosis of ovarian hormone-secreting-neoplasm in postmenopausal women. *Gynecol Oncol Rep.* 2016;15:12-15.

37. Di Bisceglie C, Brocato L, Tagliabue M, et al. Acute goserelin administration inhibits gonadotropin and androgen secretion in post-menopausal women with ovarian hyperandrogenism. *J Endocrinol Invest.* 2003;26(3):206-210.

38. Giljević Z. [Tests of adrenal gland and ovarian function in the hyperandrogenism syndrome]. *Liječnički Vjesnik.* 1996;118(Suppl 1):53-56.

39. Karam K, Hajj S. Hyperthecosis syndrome. Clinical, endocrinologic and histologic findings. *Acta Obstet Gynecol Scand.* 1979;58(1):73-79.

40. Moretti C, Toscano V. Dynamic evaluation of ovarian reserve and abnormal androgen excess in women. *J Endocrinol Invest.* 2003;26(7 Suppl):114-123.

41. Rosenfeld RL, Barnes RB, Ehrmann DA, Toledano AY. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. *J Clin Endocrinol Metab.* 2003;88(12):6115; author reply 6115; author reply 6116.

42. Sagnella F, Apa R, Guido M, et al. Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin-releasing hormone receptor antagonist in healthy women with normal ovulation versus women with polycystic ovary syndrome in the early follicular phase. *Fertil Steril.* 2009;91(5):1857-1863.

43. Samaan NA, Gates RB, Hickey RC, Rutledge FH. Endocrine studies during stimulation-suppression in hirsutism. *Obstet Gynecol.* 1975;46(1):104-108.

44. Vaikkakara S, Al-Ozairi E, Lim E, et al. The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. *Gynecol Endocrinol.* 2008;24(2):87-92.

45. Wenz AC, White RJ Jr, Migeon CJ, Hsu TH, Barnes HV, Jones GS. Differential ovarian and adrenal vein catheterization. *Ann J Obstet Gynecol.* 1976;125(7):1000-1007.

46. Abraham GE, Maroulis GB, Boysers SP, Baster JE, Magyar DM, Elsner CW. Dexamethasone suppression test in the management of hyperandrogenized patients. *Obstet Gynecol.* 1981;57(2):158-165.

47. Böhm P, Fenske M, Häfle R, König A. Limited significance of the LRH test in the diagnosis of ovarian dysfunction. *Acta Endocrinol (Copenh).* 1978;89(3):438-444.

48. Carmina E, Levin JH, Malizia G, Lobo RA. Ovine corticotropin-releasing factor and dexamethasone responses in hyperandrogenic women. *Fertil Steril.* 1990;54(2):245-250.

49. Carmina E, Stancyzk FZ, Chang L, Miles RA, Lobo RA. The ratio of androstenedione:11 beta-hydroxyandrostenedione is an important marker of adrenal androgen excess in women. *Fertil Steril.* 1992;58(1):148-152.

50. d’Alva CB, Abiven-Lepage G, Viallon V, et al. Sex steroids in androgen-secreting adrenocortical tumors: clinical and hormonal features in comparison with non-tumoral causes of androgen excess. *Eur J Endocrinol.* 2008;159(5):641-647.

51. Dai H, Lu L, Xing XP, et al. [Efficacy of medium dose dexamethasone androgen suppression test in the diagnosis of female hyperandrogenism]. *Zhonghua Yi Xue Za Zhi.* 2018;98(26):2073-2077.

52. Ettinger B, Von Werder K, Thenaers GC, Forsham PH. Plasma testosterone stimulation-suppression dynamics in hirsute women. *Am J Med.* 1971;51(2):170-175.

53. Fang M, Dong J, Zhong Q, et al. Value of diffusion-weighted imaging combined with conventional magnetic resonance
imaging in the diagnosis of thecomas and their differential diagnosis with adult granulosa cell tumors. Acta Radiol. 2019;60(11):1532-1542.

54. Geller S, Scholler R. [The concept of ovarian hyperandrogenism. Critical study in the light of the clomiphene-dexamethasone test]. Rev Fr Gynecol Obstet. 1974;69(6):393-401.

55. Hu R. Contrast enhanced ultrasonographic characteristics of ovarian thecomas-fibromas group. Chinese J Interv Imaging Ther. 2014;11(10):664-667.

56. Hudson RW, Lochnan HA, Danby FW, Margesson LJ, Strang BK, Kimmett SM. 11 beta-hydroxyandrostenedione: a marker of adrenal function in hirsutism. Fertil Steril. 1990;54(6):1065-1071.

57. Jahanfar S, Eden JA, Garrett DK. How reliable are biochemical tests in the diagnosis of polycystic ovary syndrome? Aust J Med Sci. 1994;15(3):72-74.

58. Karrer-Voegeli S, Rey F, Reymond MJ, Meuwly JY, Gaillard RC, Hudson RW, Lochnan HA, Danby FW, Margesson LJ, Strang BK, Kimmett SM. The utility of the gonadotrophin releasing hormone (GnRH) test in functionally atypical polycystic ovary syndrome by a short GnRH stimulation test]. Hum Reprod. 1974;9(6):393-401.

59. Kirschner MA, Jacobs JB. Combined ovarian and adrenal vein catheterization to determine the site(s) of androgen overproduction in hirsute women. J Clin Endocrinol Metab. 1971;33(2):209-220.

60. Koskinen P, Penttilä TA, Anttila L, Erkkola R, Irjala K. Optimal diagnostic thresholds for androgen-producing tumors or pathologies of thecomas and their differentiation in women with polycystic ovary disease in obese women with a 24-hour hormone profile after buserelin stimulation. J Reprod Med. 2000;45(3):171-178.

61. Leite V, Devesa J, Valdés L, Sobrinho LG. Study of the source(s) of hyperandrogenism in women with idiopathic hirsutism. Horm Metab Res. 1990;22(9):499-503.

62. Lewandowski KC, Cajdler-Luba A, Bienkiewicz M, Lewinski A. Women with oligo-amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria. Neuro Endocrinol Lett. 2011;32(6):847-856.

63. Lewandowski KC, Cajdler-Luba A, Salata I, Bienkiewicz M, Lewinski A. The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS). Endokrynol Pol. 2011;62(2):120-128.

64. Lopez JM, Migeon CJ, Jones GE. Hirsutism and evaluation of the dexamethasone suppression and chorionic gonadotropin stimulation test. Am J Obstet Gynecol. 1967;98(6):749-758.

65. Meden-Vrtovec H. GnRH analog administration in patients with polycystic ovarian disease. Int J Gynaecol Obstet. 1995;50(2):179-183.

66. Parker CR Jr, Bruneteau DW, Greenblatt RB, Mahesh VB. Peripheral, ovarian, and adrenal vein steroids in hirsute women: acute effects of human chorionic gonadotropin and adrenocorticotropic hormone. Fertil Steril. 1975;26(9):877-888.

67. Pasquali R, Paton L, Pocognoli P, Cognigni GE, Gambineri A. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab. 2007;92(11):4208-4217.

68. Re T, Barbetta L, Dall’Asta C, Faglia G, Ambrosi B. Comparison between buserelin and dexamethasone testing in the assessment of hirsutism. J Endocrinol Invest. 2002;25(1):84-90.

69. Rittmaster RS, Loriaux DL, Culler GB Jr. Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women. J Clin Endocrinol Metab. 1985;61(3):462-466.

70. Rittmaster RS, Thompson DL. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab. 1990;70(4):1096-1102.

71. Rosenfield RL, Ehrmann DA, Barnes RB, Sheikh Z. Gonadotropin-releasing hormone agonist as a probe for the pathogenesis and diagnosis of ovarian hyperandrogenism. Ann N Y Acad Sci. 1993;687:162-181.

72. Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod. 2011;26(11):3138-3146.
83. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. *Fertil Steril.* 2012;98(1):242-249.

84. Stahl. Serum testosterone levels in hirsute women: a comparison of adrenal, ovarian and peripheral vein values.–PubMed–NCBI. *Obstet Gynecol.* 1973;41(5):650-654.

85. Taubert HD, Dericks-Tan JS. The ovary-suppression test in the evaluation of hyperandrogenemia. *Gynecol Endocrinol.* 1990;4(2):109-118.

86. D Anna A. [The biochemical investigation of female hyperandrogenism]. *Quad Clin Ostet Ginecol.* 1963;18:653-661.

87. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. *J Clin Endocrinol Metab.* 2004;89(2):453-462.

88. Carmina E, Rosato F, Jannì A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. *J Clin Endocrinol Metab.* 2006;91(1):2-6.